Is Agenus Inc. (NASDAQ:AGEN) a buy in 2026?
Hold. Agenus Inc. is a wait-and-watch at today's price, not a fresh buy.
Botensilimab is the whole story now, and the market is pricing the coin-flip fairly at $329M.
Where AGEN is headed
Agenus in mid-2027 is a binary outcome company wearing the costume of a diversified immuno-oncology platform. The pipeline sprawl (QS-21, Retrocyte Display, a dozen collaboration antibodies with names ending in numbers) is legacy scaffolding. What actually determines the equity value from here is botensilimab plus balstilimab in refractory microsatellite-stable colorectal cancer, the disease setting where PD-1 monotherapy has failed for a decade and where a Phase 3 readout is the only thing that matters. Everything else is optionality traded for cash.
Read the full Compass Direction on AGEN
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $7.91).
See the full AGEN analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Agenus Inc. (NASDAQ:AGEN) a buy in 2026?
Hold. Agenus Inc. is a wait-and-watch at today's price, not a fresh buy. Botensilimab is the whole story now, and the market is pricing the coin-flip fairly at $329M.
What is AGEN's Compass Score?
Agenus Inc. scores 82/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for AGEN?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the AGEN page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.